Contemporary Treatment of Acute Heart Failure

Progress in Cardiovascular Diseases

Volumn 58, Issue 4, 2016, Pages 367-378

  Hsiao, Ruth ^a   Greenberg, Barry ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute heart failure; Investigational agent; Treatment

Indexed keywords

DIURETIC AGENT; DOBUTAMINE; DOPAMINE; GLYCERYL TRINITRATE; INOTROPIC AGENT; LOOP DIURETIC AGENT; METOLAZONE; MILRINONE; NESIRITIDE; NITROPRUSSIDE SODIUM; SERELAXIN; THIAZIDE DIURETIC AGENT; URODILATIN; VASODILATOR AGENT; CARDIOTONIC AGENT;

ACUTE HEART FAILURE; BLOOD PRESSURE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMORBIDITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; GLOMERULUS FILTRATION RATE; HEART EJECTION FRACTION; HEART OUTPUT; HEART PERFUSION; HEMODYNAMICS; HOSPITALIZATION; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LENGTH OF STAY; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SLOW CONTINUOUS ULTRAFILTRATION; TREATMENT OUTCOME; VASOCONSTRICTION; VENOUS CONGESTION; ACUTE DISEASE; ALGORITHM; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; HEALTH; HEART FAILURE; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; RISK FACTOR; UNITED STATES;

ACUTE DISEASE; ALGORITHMS; CARDIOTONIC AGENTS; CLINICAL TRIALS AS TOPIC; DIURETICS; DRUG THERAPY, COMBINATION; GLOBAL HEALTH; HEART FAILURE; HUMANS; LENGTH OF STAY; PREVALENCE; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES; VASODILATOR AGENTS;

EID: 84959310210     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2015.12.005     Document Type: Review

References (56)

1. Roger V.L. Epidemiology of heart failure. Circ Res 2013, 113:646-659.
2. Braunwald E. Shattuck lecture - cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997, 337:1360-1369.
3. Ho K.K., Pinsky J.L., Kannel W.B., et al. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993, 22:6A-13A.
4. Hall M.J., Levant S., DeFrances C.J. Hospitalization for congestive heart failure: United States, 2000-2010 NCHS Data Brief 2012, 1-8.
5. Kenchaiah S., Evans J.C., Levy D., et al. Obesity and the risk of heart failure. N Engl J Med 2002, 347:305-313.
6. Laribi S., Aouba A., Nikolaou M., et al. Trends in death attributed to heart failure over the past two decades in Europe. Eur J Heart Fail 2012, 14:234-239.
7. Gheorghiade M., Pang P.S. Acute heart failure syndromes. J Am Coll Cardiol 2009, 53:557-573.
8. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 2012, 125:e2-e220.
9. Liao L., Allen L.A., Whellan D.J. Economic burden of heart failure in the elderly. Pharmacoeconomics 2008, 26:447-462.
10. Jencks S.F., Williams M.V., Coleman E.A. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med 2009, 360:1418-1428.
11. Chen J., Normand S.-L.T., Wang Y., et al. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries: 1998-2008. JAMA 2011, 306:1669-1678.
12. Dharmarajan K., Hsieh A.F., Lin Z., et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA 2013, 309:355-363.
13. Ramirez A., Abelmann W.H. Cardiac decompensation. N Engl J Med 1974, 290:499-501.
14. Feltner C., Jones C.D., Cené C.W., et al. Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and meta-analysis. Ann Intern Med 2014, 160:774-784.
15. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur J Heart Fail 2012, 14:803-869.
16. Roger V.L., Weston S.A., Redfield M.M., et al. Trends in heart failure incidence and survival in a community-based population. JAMA 2004, 292:344-350.
17. Ambrosy A.P., Gheorghiade M., Chioncel O., et al. Global perspectives in hospitalized heart failure: regional and ethnic variation in patient characteristics, management, and outcomes. Curr Heart Fail Rep 2014, 11:416-427.
18. Mentz R.J., Cotter G., Cleland J.G., et al. International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. Eur J Heart Fail 2014, 16:614-624.
19. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013, 62:e147-e239.
20. Butler J., Forman D.E., Abraham W.T., et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004, 147:331-338.
21. Neurberg G.W., Miller A.B., O'Connor C.M., et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002, 144:31-38.
22. Testani J.M., Chen J., McCauley B.D., et al. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 2010, 122:265-272.
23. Ronco C., Cicoira M., McCullough P.A. Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J Am Coll Cardiol 2012, 60:1031-1042.
24. Fonarow G.C. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003, 4:S21-S30.
25. Gheorghiade M., Filippatos G., De Luca L., et al. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med 2006, 119:s3-s10.
26. Steimle A.E., Stevenson L.W., Chelimsky-Fallick C., et al. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation 1997, 96:1165-1172.
27. Forman D.E., Butler J., Wang Y., et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004, 43:61-67.
28. Felker G.M., Lee K.L., Bull D.A., et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011, 364:797-805.
29. Chen H.H., Anstrom K.J., Givertz M.M., et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE Acute Heart Failure Randomized Trial. JAMA 2013, 310:2533-2543.
30. Bart B.A., Goldsmith S.R., Lee K.L., et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012, 367:2296-2304.
31. Bart B.A. Treatment of congestion in congestive heart failure: ultrafiltration is the only rational initial treatment of volume overload in decompensated heart failure. Circ Heart Fail 2009, 2:499-504.
32. Carlson M.D., Eckman P.M. Review of vasodilators in acute decompensated heart failure: the old and the new. J Card Fail 2013, 19:478-493.
33. Elkayam U., Bitar F., Akhter M.W., et al. Intravenous nitroglycerin in the treatment of decompensated heart failure: potential benefits and limitations. J Cardiovasc Pharmacol Ther 2004, 9:227-241.
34. Guiha N.H., Cohn J.N., Mikulic E., et al. Treatment of refractory heart failure with infusion of nitroprusside. N Engl J Med 1974, 291:587-592.
35. O'Connor C.M., Starling R.C., Hernandez A.F., et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011, 365:32-42.
36. Publication Committee for the VMAC Investigators (Vasodilation in the Management of Acute CHF): intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002, 287:1531-1540.
37. Adams K.F., Fonarow G.C., Emerman C.L., et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005, 149:209-216.
38. Peacock W.F., Emerman C., Costanzo M.R., et al. Early vasoactive drugs improve heart failure outcomes. Congest Heart Fail 2009, 15:256-264.
39. Francis G.S., Bartos J.A., Adatya S. Inotropes. J Am Coll Cardiol 2014, 63:2069-2078.
40. Elkayam U., Ng T., Hatamizadeh P. Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action. Circulation 2008, 117:200-205.
41. Goldberg L.L. Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol Rev 1972, 24:1-29.
42. Bayram M., De Luca L., Massie M.B., et al. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol 2005, 96:47G-58G.
43. Sonnenblick E.H., Frishman W.H., LeJemtel T.H., et al. Dobutamine: a new synthetic cardioactive sympathetic amine. N Engl J Med 1979, 300:17-22.
44. Shipley J.B., Tolman D., Hastillo A., et al. Milrinone: basic and clinical pharmacology and acute and chronic management. Am J Med Sci 1996, 311:286-291.
45. Cuffe M.S., Califf F.M., Adams K.F., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002, 287:1541-1547.
46. Felker G.M., Benza R.L., Chandler A.B., et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003, 41:997-1003.
47. Anker S.D., Ponikowski P., Mitrovic V., et al. Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. Eur Heart J 2015, 36:715-723.
48. Goetz K., Drummer C., Zhu J.L., et al. Evidence that urodilatin, rather than ANP, regulates renal sodium excretion. J Am Soc Nephrol 1990, 1:867-874.
49. Mitrovic V., Seferovic P.M., Simeunovic D., et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 2006, 27:2823-2832.
50. Miyares M.A., Davis K.A. Serelaxin, a "breakthrough" investigational intravenous agent for acute heart failure. Pharm Ther 2013, 38:606-611.
51. Zamani P., Greenberg B.H. Novel vasodilators in heart failure. Curr Heart Fail Rep 2013, 10:1-11.
52. Teerlink J.R., Metra M., Felker G.M., et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009, 373:1429-1439.
53. Teerlink J.R., Cotter G., Davison B.A., et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013, 381:29-39.
54. Davison B.A., Metra M., Cotter G., et al. Worsening heart failure following admission for acute heart failure: a pooled analysis of the PROTECT and RELAX-AHF studies. J Am Coll Cardiol 2015, 3:395-403.
55. Metra M., Teerlink J.R., Felker G.M., et al. Dyspnea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. Eur J Heart Fail 2010, 12:1130-1139.
56. Metra M., Cotter G., Davison B.A., et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013, 61:196-206.